RRD R.R. Donnelley & Sons Company

RRD Builds on Long-Standing Supply Chain Experience to Provide Rapidly Mobilized Diagnostic Test Kit Production Solution

R.R. Donnelley & Sons Company (RRD) (NYSE: RRD), a leading global provider of marketing and business communications, today introduced a holistic supply chain solution for the production, kitting, and fulfillment of point-of-care and at-home diagnostic test kits. The solution builds upon RRD’s significant experience, processes and systems to address the increased need for end-to-end test kit production.

The COVID-19 pandemic has given rise to a significant increase in demand for virtual healthcare. A recent found that consumer adoption of telehealth has skyrocketed over the past year, with 46 percent of consumers using remote options to replace cancelled healthcare visits — compared to 11 percent in 2019. This move to virtual health has prompted the need for diagnostic testing solutions that can be self-administered from home.

To address this evolving and critical demand, RRD created a diagnostic test kit offering — an end-to-end supply chain solution that integrates and accelerates all stages of test kit production from ideation, development and production to fulfillment and supply chain management. The process also incorporates creative design, packaging and label production, and scalable execution on a global footprint. Given RRD’s existing supply chain solutions and regulatory-compliant facilities, the new solution addresses common industry challenges such as compliance, cost, and speed to market.

“At-home test kits offer patients greater convenience while limiting risks of exposure, but for companies new to the test kit space, it may be a struggle to meet the increased supply chain demands required to successfully produce a high volume of diagnostic kits,” said Ken Gammon, Vice President, RRD Healthcare Solutions. “The extra capacity from a one-stop shop partner coupled with a strategic and consultative approach leads to on-time distribution and delivery, quality assurance, and improved ROI.”

The breadth of the solution allows for the management of multiple vendors and SKUs, an abundance of supply with a reduced lead time, and the ability to manage complexities and drive internal process efficiencies.

“RRD recognizes the high level of supply chain complexity involved in the test kit production, including regulatory approval, component and equipment shortages, and logistical planning,” said John Pecaric, President, RRD Business Services. “By leveraging RRD’s existing global resources and long-standing supply chain experience, we can ensure our clients have a holistic, reliable solution as they bring diagnostic tests to the marketplace.”

The solution is part of RRD's Life Sciences Solution Suite, which top Life Sciences companies worldwide rely on to execute best in class product execution from design through production, kitting, fulfillment and distribution through our global regulatory compliant network of facilities. Find more information here: .

About RRD

RRD is a leading global provider of multichannel business communications services and marketing solutions. With more than 50,000 clients and 36,400 employees across 29 countries, RRD offers the industry’s most comprehensive offering of solutions designed to help companies—from Main Street to Wall Street—optimize customer engagement and streamline business operations across the complete customer journey. RRD offers a comprehensive portfolio of capabilities, experience and scale that enables organizations around the world to create, manage, deliver, and optimize their marketing and business communications strategies. For more information, visit the Company’s website at .

EN
16/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on R.R. Donnelley & Sons Company

Moody's Ratings affirms R.R. Donnelley & Sons Company's CFR at B3

Moody's Ratings (Moody's) has affirmed R.R. Donnelley & Sons Company's (RRD) B3 corporate family rating (CFR) and the B3-PD probability of default rating. We have also affirmed the rating on the senior secured notes at B1 and the ratings on the senior unsecured notes and junior lien senior secured n...

R.R. Donnelley & Sons Company: Covenant Quality Post-Sale Snapshot: $4...

R. R. Donnelley & Sons Company's covenant package provides lower-tier moderate protection, reflecting a CQ score of 3.21

R.R. Donnelley & Sons Company: Covenant Quality Post-Sale Snapshot: $1...

R. R. Donnelley & Sons Company's covenant package provides moderate protection, reflecting a CQ score of 3.02

Moody's Ratings upgrades secured debt to B1 and assigns Caa1 rating to...

Moody's Ratings (Moody's) has upgraded R.R. Donnelley & Sons Company's (RRD) ratings for the proposed senior secured notes to B1 from B2. The upgrade reflects the changes in the proposed debt amounts and the addition of the junior lien notes in the debt structure. At the same time, we have assigned ...

R.R. Donnelley & Sons Company: Update following proposed debt raise an...

Our credit view of this issuer reflects its positive free cash flow and its good liquidity to weather ongoing pressures, offset by its demand pressures on revenue and EBITDA.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch